Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes

Haller, Hermann, Ito, Sadayoshi, Izzo, Joseph L., Januszewicz, Andrzej, Katayama, Shigehiro, Menne, Jan, Mimran, Albert, Rabelink, Ton J. +4 more·2011·New England Journal of Medicine
DOI 10.1056/nejmoa1007994

Cited by (793)

Items 601–700 of 793

  1. Study on the Interaction of Olmesartan with Human Serum Albumin by Spectroscopic and Molecular Docking Techniques
    Monir Shalbafan, Mahdieh Sadeghpour, Abolfazl Olyaei · 2025 · Russian Journal of Physical Chemistry B
  2. Blood Pressure Targets in the 2025 AHA/ACC/Multisociety High Blood Pressure Guideline
    Ji-Guang Wang · 2025 · Journal of the American College of Cardiology
  3. Effects of Inhibitors of the Activity of the Circulating Renin–Angiotensin System on the Growth and Proliferation of Endometrial Cancer Cells
    Sarah J. Delforce, Riazuddin Mohammed, Tess L. Symington, Yu Wang, Nicole M. Verrills, Eugenie Ruth Lumbers, Kirsty G. Pringle · 2025 · International Journal of Molecular Sciences
  4. Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Ayman Alqurain, Mohsen Abdullah Alotaibi, Bandar A Alazmi, Maysun A Aljohani, Bayan R Albalawi, Danah A. Alzughaibi, Abdulziz F Alzhrani, Rafie E Ahmed, Haya Nada Alnoumesy, Shahad A Aloufi et al. · 2026 · Cureus
  5. RAAS blockade in the kidney life-cycle–treatment standard
    Diego Moriconi, Clara García-Carro, Julio E. Núñez, Ricardo Correa‐Rotter, Katherine Tuttle, María José Soler · 2026 · Nephrology Dialysis Transplantation
  6. Remission in diabetic kidney disease: current evidence and future directions
    Michael Reaume, Navdeep Tangri · 2026 · Current Opinion in Nephrology & Hypertension
  7. Diabetic Kidney Disease
    Raimund H. Pichler, Ian H. de Boer, Miguel F. Palma Diaz, Maryam Afkarian · 2012 · Springer eBooks
  8. Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG)
    Katsuyuki Ando, Masakazu Haneda, Sadayoshi Ito, Naoki Kashihara, Koichi Node, Masaomi Nangaku, Tatsuo Shimosawa, Junji Kishimoto, Toshiro Fujita · 2011 · Cardiovascular Drugs and Therapy
  9. Addressing chronic kidney disease in F ar N orth Q ueensland: gains and opportunities
    Luke J Vos, Richard Baer, Malcolm McDonald · 2013 · Australian Journal of Rural Health
  10. Blutdruck Zielwerte auf dem Prüfstand
    Jörg Slany · 2011 · Wiener klinische Wochenschrift
  11. Antihypertensive Therapy Benefits: Pleiotropic Versus Blood Pressure-Dependent Mechanisms
    Sverre Erik Kjeldsen, Gordon T. McInnes · 2012 · Springer eBooks
  12. Screening, Early Diagnosis, Genetic Markers, and Predictors of Diabetic Nephropathy
    Eric P. Cohen, Jean-Marie Krzesinski · 2014 · Springer eBooks
  13. Lessons from the novel renoprotective studies made by antihypertensive drugs
    László Bajnok · 2013 · Orvosi Hetilap
  14. Progression of Chronic Kidney Disease in Patients with Diabetes: Implications for Practice
    Michael A. Weber · 2013 · Endocrine Practice
  15. Long-term blockade of the renin–angiotensin system: an adequate evaluation is still needed
    J. Segura, Luis Miguel Ruilope · 2014 · Hypertension Research
  16. Blockade of the renin–angiotensin system for the primary prevention of diabetic nephropathy
    Merlin C. Thomas, Robert MacGinley · 2011 · Diabetes Management
  17. Presión arterial medida en la consulta y presión arterial real. ¿Son similares?
    J. Segura, Luis Miguel Ruilope · 2012 · Hipertensión y Riesgo Vascular
  18. Urinary albumin excretion regression in hypertensive individuals
    Renan Oliveira Vaz-de-Melo, José Fernando Vilela-Martin · 2012 · International Journal of Cardiology
  19. Olmesartan slows microalbuminuria
    Alexandra King · 2011 · Nature Reviews Cardiology
  20. Diabetic Nephropathy Clinical Trials: A Critical Appraisal
    Meguid El Nahas, Bo Feldt‐Rasmussen · 2015 · Springer eBooks
  21. Albuminurie
    Christos Chatzikyrkou, Hermann G. Haller, Jan Menne · 2012 · Der Internist
  22. Prevention and Treatment
    Flávio Danni Fuchs · 2017 · Springer eBooks
  23. Possibilities of using fosinopril in treatment of patients with chronic kidney disease in combination with cardiovascular diseases and diabetes mellitus
    Elizaveta Yu. Ebzeeva, Ol'ga Dmitrievna Ostroumova, Батюкина Светлана Владимировна, N. A. Shatalova, N. M. Doldo, R. R. Romanovsky · 2021 · Medical alphabet
  24. “ROADMAP” Controversies
    Debbie L. Cohen, Raymond R. Townsend · 2011 · Journal of Clinical Hypertension
  25. Blockierung des Renin-Angiotensin-Aldosteron-Systems
    Roland Schmitt · 2021 · Der Nephrologe
  26. Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents
    Yong Hoon Kim, Ae‐Young Her, Myung Ho Jeong, Byeong‐Keuk Kim, Sung‐Jin Hong, Sang‐Ho Park, Seunghwan Kim, Chul‐Min Ahn, Jung‐Sun Kim, Young‐Guk Ko et al. · 2021 · Cardiology Journal
  27. Hemmstoffe des Renin-Angiotensin-Systems
    Manfred Anlauf, Franz Weber · 2016 · Springer eBooks
  28. Diseases of Renal Microcirculation: Diabetic Nephropathy
    Ineke J. Riphagen, Hiddo J.L. Heerspink, Rijk O. B. Gans, Sandrine Gaillard · 2015 · Springer eBooks
  29. Hemmstoffe des Renin-Angiotensin-Systems
    Manfred Anlauf, Franz Weber · 2015 · Springer eBooks
  30. Diabetic Nephropathy
    Maria Elba Bandeira de Farias, Deborah Queiroz, Fernanda Moura Victor · 2022 · Springer eBooks
  31. Comprehensive assessment of cardiovascular complications in a patient with type 1 diabetes mellitus, chronic kidney disease and diabetic neuroosteoarthropathy
    O. N. Bondarenko, M. V. Yaroslavceva, Alla Yur'evna Tokmakova, Gagik Radikovich Galstyan, Natalia V. Tarbaeva · 2022 · Almanac of Clinical Medicine
  32. Goals of Therapy: Slowing Progression and Dyslipidemias
    M. Salman Singapuri, Janice P. Lea · 2012 · Springer eBooks
  33. Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)
    Christoph H. Saely, Gerit-Holger Schernthaner, Johanna Maria Brix, Renate Klauser‐Braun, Emanuel Zitt, Heinz Drexel, Guntram Schernthaner · 2023 · Wiener klinische Wochenschrift
  34. Efficacy of Aldosterone Antagonist with RAAS Blockade in Patients with Diabetic Kidney Disease
    Arvind Gupta, Upma Narain · 2018 · Archives of Nephrology
  35. Introduction of Renin-Angiotensin-Aldosterone System (RAAS)
    Mukesh Nandave · 2024 · Springer eBooks
  36. Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker
    Sadanand Shetty, Anil Bhoraskar, Banshi Saboo, Satyanarayan Routray, MANGESH HARIHAR TIWASKAR, L. Sreenivasa Murthy, Vijay Kumar Shrivas, Anooja Jose, Charmy Prajapati, Amit Qamra et al. · 2024 · Journal of the Association of Physicians of India
  37. Proteinuria-Microalbuminuria in Renal Damage
    Josep Redón, Gernot Pichler, Fernando Martínez · 2015 · Springer eBooks
  38. Olmesartan for microalbuminuria—friend or foe?
    Linda Koch · 2011 · Nature Reviews Endocrinology
  39. Verminderung der Progression einer chronischen Niereninsuffizienz
    Daniel Sollinger, Beate Schamberger, Julia Weinmann‐Menke, Jens Lutz · 2016 · Der Nephrologe
  40. MICROALBUMINURIA; “COMPARISON OF LOSARTAN POTASSIUM AND LISINOPRIL IN TREATMENT OF PATIENTS WITH TYPE II DIABETES MELLITUS”
    Ghazanfar Ali Sandhu, Ghulam Abbas Tahir, Zaheer Ahmad, Aqeel Maqsood Anjum · 2017 · The Professional Medical Journal
  41. Diabetes and the Kidney
    Anna Solini, Pietro Castellino · 2019 · Endocrinology
  42. ARTERIAL HYPERTENSION WORKGROUP RESOLUTION. THE ROLE OF SARTANS IN TREATMENT OF SYSTEMIC HYPERTENSION IN THE 21ST CENTURY
    А. О. Конради, О. N. Zhdanova, О. P. Rotar, Yu. A. Karpov, Valery I. Podzolkov, P. A. Lebedev, Anna I. Chesnikova, Д. В. Небиеридзе, O. N. Miller, Elena Solovjova et al. · 2018 · Russian Journal of Cardiology
  43. Diabetes Mellitus
    Radica Z. Alicic, Katherine R. Tuttle · 2017 · Elsevier eBooks
  44. Effects of angiotensin II receptor blockers on the course of the disease in patients with stable ischemic heart disease
    Anastasia M. Kochergina, N. А. Kochergin · 2022 · Complex Issues of Cardiovascular Diseases
  45. Diabetic Nephropathy
    Elba Bandeira, Deborah Queiroz · 2013 · Springer eBooks
  46. Diabetische Nephropathie
    Alexander Sämann, Günter Wolf · 2013 · Der Nephrologe
  47. Diabetic Kidney Disease: Identification, Prevention, and Treatment
    M. L. Caramori, Peter R Rossing · 2022 · Springer eBooks
  48. Precision Medicine Approaches for Management of Type 2 Diabetes
    David Chen, Jordan Fulcher, EMMA S. SCOTT, Alicia Josephine Jenkins · 2022 · Springer eBooks
  49. Reducing Progression of Diabetic Nephropathy by Antihypertensive Treatment
    Anita Hansen, Ivo Quack, Lars Christian Rump · 2012
  50. Arterial hypertension in diabetes: etiology and treatment
    Colleen Ann Flynn, George L. Bakris · 2015
  51. Prevention of diabetic microvascular complications
    Alice P.S. Kong, Juliana C.N. Chan · 2015
  52. Prevalence of and clinical characteristics associated with microalbuminuria in hypertension
    Adel Alharf · 2012 · Enlighten: Theses (The University of Glasgow)
  53. Uso de olmesartán en la prevención o retraso de la nefropatía diabética: algunas consideraciones
    Ferrán Catalá-López, Gloria Martín-Serrano, Miguel Angel Maciá, Dolores Montero · 2012 · Revista Española de Cardiología
  54. Authors' reply to Laragh and Sealey
    Franz H. Messerli, Harikrishna J. Makani, Sripal Bangalore · 2013 · BMJ
  55. When Blockade of the Renin-Angiotensin System Becomes a Two-Edged Sword
    Theodore W. Kurtz · 2013 · American Journal of Hypertension
  56. Patient-centered blood pressure: Thresholds, targets, and tools in diabetes
    Sanjay Kalra, Kamal Kishor, Yashdeep Gupta · 2017 · Indian Journal of Endocrinology and Metabolism
  57. Olmesartan induced gastroenteropathy and acute kidney injury: A case report and review of literature
    2020
  58. Diabetic Nephropathy
    Sally M. Marshall, Allan Flyvbjerg · 2016
  59. Optimization of sudden cardiac death prevention in type 2 diabetes in France : a public health simulation study on a realistic virtual population
    Hai-Ha Le · 2017 · theses.fr (ABES)
  60. Hypertension in Diabetes Mellitus
    W.J. Elliott · 2014 · Springer eBooks
  61. Albuminurie als Risikofaktor und Marker der Endorganschädigung in der Hypertonie
    Christos Chatzikyrkou, Hermann G. Haller · 2011 · Der Nephrologe
  62. Was gibt es Neues in der Hypertonie?
    Joachim D. Hoyer, Hermann G. Haller · 2011 · Der Nephrologe
  63. Off-target effects of RAAS-inhibition: importance on renal outcomes in patients with diabetes
    Miao Yan · 2012 · University of Groningen research database (University of Groningen / Centre for Information Technology)
  64. Fallbericht: Nierenarterienstenose bei geplanter CABG: Therapeutische Strategien
    Ulrich Harler, Martin Manninger-Wünscher, Robert Zweiker · 2013 · Journal für Kardiologie (Krause & Pachernegg GmbH)
  65. Decreasing Arterial Stiffness and/or Wave Reflections Independently of Mean Arterial Pressure: Effect of Antihypertensive Drugs (Part 1)
    Hélène Beaussier, Stéphane Laurent, Pierre Boutouyrie · 2014 · Springer eBooks
  66. Prevention and Regression of Chronic Kidney Disease and Hypertension
    Hiroyuki Sasamura · 2012 · InTech eBooks
  67. Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP)
    Eberhard Ritz · 2011 · Polskie Archiwum Medycyny Wewnętrznej
  68. Leczenie nadciśnienia tętniczego u chorych na przewlekłą chorobę nerek
    Marcin Adamczak, Andrzej Więcek · 2011 · Via Medica Journals
  69. Efecto de la supresión crónica del sistema renina-angiotensina sobre la excreción urinaria de albumina en pacientes con hipertensión arterial
    Cesar Cerezo Olmos · 2012 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  70. It Takes the Right Medications to Prevent a Million Heart Attacks and Strokes
    James J. DiNicolantonio, Flávio Danni Fuchs, James Henry O’Keefe · 2014 · Postgraduate Medicine
  71. Increased Mortality in Patients With Diabetes Associated With Olmesartan for the Prevention/Delay of Microalbuminuria Onset: a Matter of Concern?
    Luciano Consuegra‐Sánchez, Juan Sanchís, Julio E. Núñez, José Domingo Cascón, Manuel Villegas, Francisco Picó · 2011 · Revista Española de Cardiología (English Edition)
  72. Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion
    Matthew Weir · 2015 · Journal of Indian College of Cardiology
  73. Optimal blood pressure targets in 2014 – Does the guideline recommendation match the evidence base?
    C A Alviar, Sripal Bangalore, Franz H. Messerli · 2015 · Hipertensión y Riesgo Vascular
  74. HTA et diabète : nouveaux niveaux de preuves et prise en charge
    B Chamontin, Béatrice Bouhanick · 2011 · Archives des Maladies du Coeur et des Vaisseaux - Pratique
  75. Uso de olmesartán en la prevención o retraso de la nefropatía diabética: algunas consideraciones. Respuesta
    Luciano Consuegra‐Sánchez, Julio E. Núñez, Francisco Picó, Juan Sanchís · 2012 · Revista Española de Cardiología
  76. The spectrum of albuminuria as a predictor of cardiorenal outcomes
    Ivana Lazich, George L. Bakris · 2011 · Therapy
  77. Risk Factors Associated with Arterial Stiffness in Diabetic Nephropathy in an Asian Population Cohort
    Lim Su-Chi, Phua E Joo, Sharon F Nne, Amizah B Asrap, Wong Melvin, Clara Si Hua Tan, Liu Jun, Toy W Ching, Ng Wei, L. Glover Dawn et al. · 2011 · Journal of the ASEAN Federation of Endocrine Societies
  78. Evolución de la enfermedad cardiorrenal bajo la supresión crónica del sistema renina-angiotensina
    César Cerezo, L. Muñiz · 2013 · Hipertensión y Riesgo Vascular
  79. Current Issues on the Angiotensin II Receptor Blocker in Cardiovascular Disease
    Hyun Ju Yoon, Kye Hun Kim · 2012 · Journal of the Korean Society of Hypertension
  80. Olmesartan for the Prevention or Delay of Diabetic Nephropathy: Some Considerations. Response
    Luciano Consuegra‐Sánchez, Julio E. Núñez, Francisco Picó, Juan Sanchís · 2012 · Revista Española de Cardiología (English Edition)
  81. Olmesartan to Prevent the Development of Microalbuminuria: Is It New? Is It True? Is It Important?
    Jamie P. Dwyer, Julia Breyer Lewis · 2011 · American Journal of Kidney Diseases
  82. Antagonistas de los receptores de la angiotensina II en el tratamiento de la hipertensión arterial, las enfermedades cardiovasculares y las renales. Realidad y futuro
    Alejandro de la Sierra · 2013 · Hipertensión y Riesgo Vascular
  83. Olmesartán: evidencia y práctica clínica
    Francisco J. Morales‐Olivas · 2013 · Hipertensión y Riesgo Vascular
  84. ROADMAP: the road to renoprotection?
    Sara S. Roscioni, Hiddo J.L. Heerspink, Dick de Zeeuw · 2011 · Nature Reviews Nephrology
  85. Albuminuria and Cardiovascular Risk
    David M. Charytan · 2011 · Clinical Journal of the American Society of Nephrology
  86. Diabetes mellitus e hipertensión: importancia del cribado de albuminuria
    Margarita Delgado Córdova, Juan Carlos Peñaloza · 2015 · Revista médica de Chile
  87. Low Dose Irbesartan Has a Renoprotective Effect as High Dose Ramipril in Diabetic Rats Treated with Insulin
    Abdulmonim A. Alqasim, Sami H. Hammadi, Ghazi A. Bamagous, Essam Eldin Mohamed Nour Eldin, Hussam H. Madi · 2015 · Open Journal of Endocrine and Metabolic Diseases
  88. Updates in the management of diabetic nephropathy
    Jai Prakash · 2015 · Clinical Queries Nephrology
  89. Cardiovascular Prevention in Diabetes Mellitus
    Dimitrios T. Farmakis, John Parissis, Gerasimos S Filippatos · 2014 · Journal of the American College of Cardiology
  90. ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
    Victor Fomin · 2013 · CARDIOVASCULAR THERAPY AND PREVENTION
  91. Proteinurie
    Jan Menne, Christos Chatzikyrkou, Hermann G. Haller · 2012 · Der Nephrologe
  92. 2. Therapeutic Strategy for Diabetic Nephropathy.
    Daisuke Koya · 2011 · Nihon Naika Gakkai Zasshi
  93. Intrarenal renin-angiotensin system activation and urinary angiotensinogen as a novel biomarker of nephropathy in childhood
    Maki Urushihara · 2012 · Japanese journal of pediatric nephrology
  94. Landscape of Combination Therapy – Which Way Forward? Proceedings of the Satellite Symposium Held at the ESH European Meeting on Hypertension and Cardiovascular Protection, 27 April 2012, London
    Patricia Fonseca, Anna F. Dominiczak, Stephen B. Harrap · 2012 · European Cardiology Review
  95. Targeting albuminuria in arterial hypertension and diabetes
    Christos Chatzikyrkou, Jan Menne · 2012 · Journal of Hypertension
  96. Patient with Essential Hypertension and Proteinuria
    Giuliano Tocci · 2015 · Practical case studies in hypertension management
  97. Different Antidiabetic Regimens and the Development of Renal Dysfunction in US Veterans with Type 2 Diabetes Mellitus
    Elvira O. Gosmanova, Robert B. Canada, Jim Y. Wan, Therese A. Mangold, Barry M. Wall · 2012 · Journal of Investigative Medicine
  98. 7. Diabetic Nephropathy
    Takashi Wada · 2013 · Nihon Naika Gakkai Zasshi
  99. V. Points of Hypertension Treatment for the Patients Complicated by Kidney Diseases and Diabetes
    Masami Tanaka, Hiroshi Itoh · 2015 · Nihon Naika Gakkai Zasshi
  100. Clinical Applications of Renin–Angiotensin System Inhibitors
    Michel Burnier · 2012